
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is anticipated to raise its FY26 revenue and EPS guidance due to positive performance in the first fiscal quarter and favorable external factors such as currency fluctuations and tariff reductions. The company is expected to experience stronger growth in its Cardiac Ablation segment as the Affera product is set to enter full launch, indicating a competitive edge over its peers. Additionally, ongoing technological advancements are projected to enhance procedural outcomes, further bolstering Medtronic's financial position and outlook.
Bears say
The outlook for Medtronic's stock appears negative due to anticipated revenue growth slowing to low-single digits, driven by challenges such as unsuccessful new product launches and market share decline in certain categories. Additionally, the bear case suggests a flat or declining operating margin, which could lead to earnings that fall below consensus expectations, exacerbated by competitive pressures and adverse currency impacts. Lastly, potential risks such as the commercialization hurdles of key products and the near-term dilution from acquisitions present further headwinds to the company's financial performance.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares